MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
Identifieur interne : 000112 ( Main/Corpus ); précédent : 000111; suivant : 000113MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
Auteurs : Irene Litvan ; Dag Aarsland ; Charles H. Adler ; Jennifer G. Goldman ; Jaime Kulisevsky ; Brit Mollenhauer ; Maria C. Rodriguez-Oroz ; Alexander I. Tröster ; Daniel WeintraubSource :
- Movement Disorders [ 0885-3185 ] ; 2011-08-15.
English descriptors
Abstract
There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease–mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%–38.2%) of nondemented patients with Parkinson's disease have mild cognitive impairment. The frequency of Parkinson's disease–mild cognitive impairment increases with age, disease duration, and disease severity. Impairments occur in a range of cognitive domains, but single domain impairment is more common than multiple domain impairment, and within single domain impairment, nonamnestic is more common than amnestic impairment. A high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time. The primary conclusions of the Task Force are that: (1) Parkinson's disease–mild cognitive impairment is common, (2) there is significant heterogeneity within Parkinson's disease–mild cognitive impairment in the number and types of cognitive domain impairments, (3) Parkinson's disease–mild cognitive impairment appears to place patients at risk of progressing to dementia, and (4) formal diagnostic criteria for Parkinson's disease–mild cognitive impairment are needed. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23823
Links to Exploration step
ISTEX:D54A384E259CBCEAF0CE4887C68236F008032EDALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI</title><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Division of Movement Disorders, Department of Neurology, University of Louisville, Louisville, Kentucky, USA, and Movement Disorders Program, Frazier Rehab Neuroscience Institute, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Centre for Age‐Related Medicine, Stavanger University Hospital and Akershus University Hospital/University of Oslo, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA</mods:affiliation></affiliation></author><author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name><affiliation><mods:affiliation>Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Movement Disorders Unit, Neurology Department, Sant Pau Hospital and Institute of Biomedical Research (IIB Sant Pau), Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Mollenhauer, Brit" sort="Mollenhauer, Brit" uniqKey="Mollenhauer B" first="Brit" last="Mollenhauer">Brit Mollenhauer</name><affiliation><mods:affiliation>Paracelsus‐Elena‐Klinik, Kassel and Georg‐August University Goettingen, Goettingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Rodriguez Roz, Maria C" sort="Rodriguez Roz, Maria C" uniqKey="Rodriguez Roz M" first="Maria C." last="Rodriguez-Oroz">Maria C. Rodriguez-Oroz</name><affiliation><mods:affiliation>Department of Neurology, Clinic Universidad de Navarra, Medical School, Neuroscience Center, CIMA, Pamplona, Centros de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Current address for Maria C. Rodriguez‐Oroz: Department of Neurology, Hospital Donostia and BioDonostia, San Sebastian, Spain</mods:affiliation></affiliation></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name><affiliation><mods:affiliation>Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D54A384E259CBCEAF0CE4887C68236F008032EDA</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23823</idno><idno type="url">https://api.istex.fr/document/D54A384E259CBCEAF0CE4887C68236F008032EDA/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000112</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI</title><author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name><affiliation><mods:affiliation>Division of Movement Disorders, Department of Neurology, University of Louisville, Louisville, Kentucky, USA, and Movement Disorders Program, Frazier Rehab Neuroscience Institute, Louisville, Kentucky, USA</mods:affiliation></affiliation></author><author><name sortKey="Aarsland, Dag" sort="Aarsland, Dag" uniqKey="Aarsland D" first="Dag" last="Aarsland">Dag Aarsland</name><affiliation><mods:affiliation>Centre for Age‐Related Medicine, Stavanger University Hospital and Akershus University Hospital/University of Oslo, Oslo, Norway</mods:affiliation></affiliation></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA</mods:affiliation></affiliation></author><author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G." last="Goldman">Jennifer G. Goldman</name><affiliation><mods:affiliation>Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name><affiliation><mods:affiliation>Movement Disorders Unit, Neurology Department, Sant Pau Hospital and Institute of Biomedical Research (IIB Sant Pau), Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Mollenhauer, Brit" sort="Mollenhauer, Brit" uniqKey="Mollenhauer B" first="Brit" last="Mollenhauer">Brit Mollenhauer</name><affiliation><mods:affiliation>Paracelsus‐Elena‐Klinik, Kassel and Georg‐August University Goettingen, Goettingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Rodriguez Roz, Maria C" sort="Rodriguez Roz, Maria C" uniqKey="Rodriguez Roz M" first="Maria C." last="Rodriguez-Oroz">Maria C. Rodriguez-Oroz</name><affiliation><mods:affiliation>Department of Neurology, Clinic Universidad de Navarra, Medical School, Neuroscience Center, CIMA, Pamplona, Centros de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Current address for Maria C. Rodriguez‐Oroz: Department of Neurology, Hospital Donostia and BioDonostia, San Sebastian, Spain</mods:affiliation></affiliation></author><author><name sortKey="Troster, Alexander I" sort="Troster, Alexander I" uniqKey="Troster A" first="Alexander I." last="Tröster">Alexander I. Tröster</name><affiliation><mods:affiliation>Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation><mods:affiliation>Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-08-15">2011-08-15</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1814">1814</biblScope><biblScope unit="page" to="1824">1824</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D54A384E259CBCEAF0CE4887C68236F008032EDA</idno><idno type="DOI">10.1002/mds.23823</idno><idno type="ArticleID">MDS23823</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>mild cognitive impairment</term><term>systematic review</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease–mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%–38.2%) of nondemented patients with Parkinson's disease have mild cognitive impairment. The frequency of Parkinson's disease–mild cognitive impairment increases with age, disease duration, and disease severity. Impairments occur in a range of cognitive domains, but single domain impairment is more common than multiple domain impairment, and within single domain impairment, nonamnestic is more common than amnestic impairment. A high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time. The primary conclusions of the Task Force are that: (1) Parkinson's disease–mild cognitive impairment is common, (2) there is significant heterogeneity within Parkinson's disease–mild cognitive impairment in the number and types of cognitive domain impairments, (3) Parkinson's disease–mild cognitive impairment appears to place patients at risk of progressing to dementia, and (4) formal diagnostic criteria for Parkinson's disease–mild cognitive impairment are needed. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Irene Litvan MD</name><affiliations><json:string>Division of Movement Disorders, Department of Neurology, University of Louisville, Louisville, Kentucky, USA, and Movement Disorders Program, Frazier Rehab Neuroscience Institute, Louisville, Kentucky, USA</json:string></affiliations></json:item><json:item><name>Dag Aarsland MD, PhD</name><affiliations><json:string>Centre for Age‐Related Medicine, Stavanger University Hospital and Akershus University Hospital/University of Oslo, Oslo, Norway</json:string></affiliations></json:item><json:item><name>Charles H. Adler MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA</json:string></affiliations></json:item><json:item><name>Jennifer G. Goldman MD, MS</name><affiliations><json:string>Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Jaime Kulisevsky MD, PhD</name><affiliations><json:string>Movement Disorders Unit, Neurology Department, Sant Pau Hospital and Institute of Biomedical Research (IIB Sant Pau), Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</json:string></affiliations></json:item><json:item><name>Brit Mollenhauer MD</name><affiliations><json:string>Paracelsus‐Elena‐Klinik, Kassel and Georg‐August University Goettingen, Goettingen, Germany</json:string></affiliations></json:item><json:item><name>Maria C. Rodriguez‐Oroz MD, PhD</name><affiliations><json:string>Department of Neurology, Clinic Universidad de Navarra, Medical School, Neuroscience Center, CIMA, Pamplona, Centros de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</json:string><json:string>Current Address: Current address for Maria C. Rodriguez‐Oroz: Department of Neurology, Hospital Donostia and BioDonostia, San Sebastian, Spain</json:string></affiliations></json:item><json:item><name>Alexander I. Tröster PhD</name><affiliations><json:string>Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA</json:string></affiliations></json:item><json:item><name>Daniel Weintraub MD</name><affiliations><json:string>Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>mild cognitive impairment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>systematic review</value></json:item></subject><articleId><json:string>MDS23823</json:string></articleId><language><json:string>eng</json:string></language><abstract>There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease–mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%–38.2%) of nondemented patients with Parkinson's disease have mild cognitive impairment. The frequency of Parkinson's disease–mild cognitive impairment increases with age, disease duration, and disease severity. Impairments occur in a range of cognitive domains, but single domain impairment is more common than multiple domain impairment, and within single domain impairment, nonamnestic is more common than amnestic impairment. A high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time. The primary conclusions of the Task Force are that: (1) Parkinson's disease–mild cognitive impairment is common, (2) there is significant heterogeneity within Parkinson's disease–mild cognitive impairment in the number and types of cognitive domain impairments, (3) Parkinson's disease–mild cognitive impairment appears to place patients at risk of progressing to dementia, and (4) formal diagnostic criteria for Parkinson's disease–mild cognitive impairment are needed. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>7.472</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1553</abstractCharCount><pdfWordCount>7095</pdfWordCount><pdfCharCount>48201</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>206</abstractWordCount></qualityIndicators><title>MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI</title><genre><json:string>review-article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>11</total><last>1824</last><first>1814</first></pages><issn><json:string>0885-3185</json:string></issn><issue>10</issue><subject><json:item><value>Reviews</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23823</json:string></doi><id>D54A384E259CBCEAF0CE4887C68236F008032EDA</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D54A384E259CBCEAF0CE4887C68236F008032EDA/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D54A384E259CBCEAF0CE4887C68236F008032EDA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D54A384E259CBCEAF0CE4887C68236F008032EDA/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Irene Litvan was funded by 5R01AG024040‐04. Charles Adler has been a consultant for Ipsen and Merck Serono, has been on the advisory boards of Biogen Idec, Eli Lilly, Medtronic, and Merz, and has received grants from the Arizona Biomedical Research Commission and the Michael J. Fox Foundation. Alexander I. Tröster has been a consultant for Medtronic, Inc., St. Jude, and Boston Scientific, has been on the advisory boards of Medtronic, Inc. and St. Jude, has received honoraria from Medtronic and Boehringer Ingelheim, and has received grants from the National Parkinson Foundation, GlaxoSmithKline, and Medtronic, Inc.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI</title><author><persName><forename type="first">Irene</forename><surname>Litvan</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Movement Disorders, Department of Neurology, University of Louisville School of Medicine, 220 Abraham Flexner Way, Ste. 1503, Louisville, KY 40241, USA</p></note><affiliation>Division of Movement Disorders, Department of Neurology, University of Louisville, Louisville, Kentucky, USA, and Movement Disorders Program, Frazier Rehab Neuroscience Institute, Louisville, Kentucky, USA</affiliation></author><author><persName><forename type="first">Dag</forename><surname>Aarsland</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Centre for Age‐Related Medicine, Stavanger University Hospital and Akershus University Hospital/University of Oslo, Oslo, Norway</affiliation></author><author><persName><forename type="first">Charles H.</forename><surname>Adler</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA</affiliation></author><author><persName><forename type="first">Jennifer G.</forename><surname>Goldman</surname></persName><roleName type="degree">MD, MS</roleName><affiliation>Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Jaime</forename><surname>Kulisevsky</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Movement Disorders Unit, Neurology Department, Sant Pau Hospital and Institute of Biomedical Research (IIB Sant Pau), Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation></author><author><persName><forename type="first">Brit</forename><surname>Mollenhauer</surname></persName><roleName type="degree">MD</roleName><affiliation>Paracelsus‐Elena‐Klinik, Kassel and Georg‐August University Goettingen, Goettingen, Germany</affiliation></author><author><persName><forename type="first">Maria C.</forename><surname>Rodriguez‐Oroz</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Clinic Universidad de Navarra, Medical School, Neuroscience Center, CIMA, Pamplona, Centros de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation><affiliation>Current Address: Current address for Maria C. Rodriguez‐Oroz: Department of Neurology, Hospital Donostia and BioDonostia, San Sebastian, Spain</affiliation></author><author><persName><forename type="first">Alexander I.</forename><surname>Tröster</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA</affiliation></author><author><persName><forename type="first">Daniel</forename><surname>Weintraub</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-08-15"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1814">1814</biblScope><biblScope unit="page" to="1824">1824</biblScope></imprint></monogr><idno type="istex">D54A384E259CBCEAF0CE4887C68236F008032EDA</idno><idno type="DOI">10.1002/mds.23823</idno><idno type="ArticleID">MDS23823</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease–mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%–38.2%) of nondemented patients with Parkinson's disease have mild cognitive impairment. The frequency of Parkinson's disease–mild cognitive impairment increases with age, disease duration, and disease severity. Impairments occur in a range of cognitive domains, but single domain impairment is more common than multiple domain impairment, and within single domain impairment, nonamnestic is more common than amnestic impairment. A high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time. The primary conclusions of the Task Force are that: (1) Parkinson's disease–mild cognitive impairment is common, (2) there is significant heterogeneity within Parkinson's disease–mild cognitive impairment in the number and types of cognitive domain impairments, (3) Parkinson's disease–mild cognitive impairment appears to place patients at risk of progressing to dementia, and (4) formal diagnostic criteria for Parkinson's disease–mild cognitive impairment are needed. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>mild cognitive impairment</term></item><item><term>Parkinson's disease</term></item><item><term>systematic review</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Reviews</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-02-28">Received</change><change when="2011-05-12">Registration</change><change when="2011-08-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D54A384E259CBCEAF0CE4887C68236F008032EDA/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/mds.v26.10</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2011-08-15">15 August 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23823</doi><idGroup><id type="unit" value="MDS23823"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Reviews</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-02-28"></event><event type="manuscriptRevised" date="2011-05-09"></event><event type="manuscriptAccepted" date="2011-05-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-06-09"></event><event type="publishedOnlineFinalForm" date="2011-08-26"></event><event type="firstOnline" date="2011-06-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1814</numbering><numbering type="pageLast">1824</numbering></numberingGroup><correspondenceTo>Movement Disorders, Department of Neurology, University of Louisville School of Medicine, 220 Abraham Flexner Way, Ste. 1503, Louisville, KY 40241, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23823.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="109"></count><count type="wordTotal" number="10840"></count></countGroup><titleGroup><title type="main" xml:lang="en">MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Critical Review PD‐MCI</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Irene</givenNames><familyName>Litvan</familyName><degrees>MD</degrees></personName><contactDetails><email>i.litvan@louisville.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Dag</givenNames><familyName>Aarsland</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Charles H.</givenNames><familyName>Adler</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Jennifer G.</givenNames><familyName>Goldman</familyName><degrees>MD, MS</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Jaime</givenNames><familyName>Kulisevsky</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Brit</givenNames><familyName>Mollenhauer</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7" currentRef="#curr1"><personName><givenNames>Maria C.</givenNames><familyName>Rodriguez‐Oroz</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Alexander I.</givenNames><familyName>Tröster</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Daniel</givenNames><familyName>Weintraub</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Division of Movement Disorders, Department of Neurology, University of Louisville, Louisville, Kentucky, USA, and Movement Disorders Program, Frazier Rehab Neuroscience Institute, Louisville, Kentucky, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="NO" type="organization"><unparsedAffiliation>Centre for Age‐Related Medicine, Stavanger University Hospital and Akershus University Hospital/University of Oslo, Oslo, Norway</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="ES" type="organization"><unparsedAffiliation>Movement Disorders Unit, Neurology Department, Sant Pau Hospital and Institute of Biomedical Research (IIB Sant Pau), Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="DE" type="organization"><unparsedAffiliation>Paracelsus‐Elena‐Klinik, Kassel and Georg‐August University Goettingen, Goettingen, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="ES" type="organization"><unparsedAffiliation>Department of Neurology, Clinic Universidad de Navarra, Medical School, Neuroscience Center, CIMA, Pamplona, Centros de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="US" type="organization"><unparsedAffiliation>Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="curr1" countryCode="ES"><unparsedAffiliation>Current address for Maria C. Rodriguez‐Oroz: Department of Neurology, Hospital Donostia and BioDonostia, San Sebastian, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">mild cognitive impairment</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">systematic review</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease–mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%–38.2%) of nondemented patients with Parkinson's disease have mild cognitive impairment. The frequency of Parkinson's disease–mild cognitive impairment increases with age, disease duration, and disease severity. Impairments occur in a range of cognitive domains, but single domain impairment is more common than multiple domain impairment, and within single domain impairment, nonamnestic is more common than amnestic impairment. A high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time. The primary conclusions of the Task Force are that: (1) Parkinson's disease–mild cognitive impairment is common, (2) there is significant heterogeneity within Parkinson's disease–mild cognitive impairment in the number and types of cognitive domain impairments, (3) Parkinson's disease–mild cognitive impairment appears to place patients at risk of progressing to dementia, and (4) formal diagnostic criteria for Parkinson's disease–mild cognitive impairment are needed. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Relevant conflicts of interest/financial disclosures: Irene Litvan was funded by 5R01AG024040‐04. Charles Adler has been a consultant for Ipsen and Merck Serono, has been on the advisory boards of Biogen Idec, Eli Lilly, Medtronic, and Merz, and has received grants from the Arizona Biomedical Research Commission and the Michael J. Fox Foundation. Alexander I. Tröster has been a consultant for Medtronic, Inc., St. Jude, and Boston Scientific, has been on the advisory boards of Medtronic, Inc. and St. Jude, has received honoraria from Medtronic and Boehringer Ingelheim, and has received grants from the National Parkinson Foundation, GlaxoSmithKline, and Medtronic, Inc.</p></note><note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Critical Review PD‐MCI</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI</title></titleInfo><name type="personal"><namePart type="given">Irene</namePart><namePart type="family">Litvan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Movement Disorders, Department of Neurology, University of Louisville, Louisville, Kentucky, USA, and Movement Disorders Program, Frazier Rehab Neuroscience Institute, Louisville, Kentucky, USA</affiliation><description>Correspondence: Movement Disorders, Department of Neurology, University of Louisville School of Medicine, 220 Abraham Flexner Way, Ste. 1503, Louisville, KY 40241, USA</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dag</namePart><namePart type="family">Aarsland</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Centre for Age‐Related Medicine, Stavanger University Hospital and Akershus University Hospital/University of Oslo, Oslo, Norway</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Charles H.</namePart><namePart type="family">Adler</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jennifer G.</namePart><namePart type="family">Goldman</namePart><namePart type="termsOfAddress">MD, MS</namePart><affiliation>Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jaime</namePart><namePart type="family">Kulisevsky</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Movement Disorders Unit, Neurology Department, Sant Pau Hospital and Institute of Biomedical Research (IIB Sant Pau), Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Brit</namePart><namePart type="family">Mollenhauer</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Paracelsus‐Elena‐Klinik, Kassel and Georg‐August University Goettingen, Goettingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maria C.</namePart><namePart type="family">Rodriguez‐Oroz</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Clinic Universidad de Navarra, Medical School, Neuroscience Center, CIMA, Pamplona, Centros de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain</affiliation><affiliation>Current Address: Current address for Maria C. Rodriguez‐Oroz: Department of Neurology, Hospital Donostia and BioDonostia, San Sebastian, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexander I.</namePart><namePart type="family">Tröster</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Weintraub</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Psychiatry and Neurology, University of Pennsylvania School of Medicine, and Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-08-15</dateIssued><dateCaptured encoding="w3cdtf">2011-02-28</dateCaptured><dateValid encoding="w3cdtf">2011-05-12</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">109</extent><extent unit="words">10840</extent></physicalDescription><abstract lang="en">There is controversy regarding the definition and characteristics of mild cognitive impairment in Parkinson's disease. The Movement Disorder Society commissioned a Task Force to critically evaluate the literature and determine the frequency and characteristics of Parkinson's disease–mild cognitive impairment and its association with dementia. A comprehensive PubMed literature review was conducted using systematic inclusion and exclusion criteria. A mean of 26.7% (range, 18.9%–38.2%) of nondemented patients with Parkinson's disease have mild cognitive impairment. The frequency of Parkinson's disease–mild cognitive impairment increases with age, disease duration, and disease severity. Impairments occur in a range of cognitive domains, but single domain impairment is more common than multiple domain impairment, and within single domain impairment, nonamnestic is more common than amnestic impairment. A high proportion of patients with Parkinson's disease–mild cognitive impairment progress to dementia in a relatively short period of time. The primary conclusions of the Task Force are that: (1) Parkinson's disease–mild cognitive impairment is common, (2) there is significant heterogeneity within Parkinson's disease–mild cognitive impairment in the number and types of cognitive domain impairments, (3) Parkinson's disease–mild cognitive impairment appears to place patients at risk of progressing to dementia, and (4) formal diagnostic criteria for Parkinson's disease–mild cognitive impairment are needed. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Irene Litvan was funded by 5R01AG024040‐04. Charles Adler has been a consultant for Ipsen and Merck Serono, has been on the advisory boards of Biogen Idec, Eli Lilly, Medtronic, and Merz, and has received grants from the Arizona Biomedical Research Commission and the Michael J. Fox Foundation. Alexander I. Tröster has been a consultant for Medtronic, Inc., St. Jude, and Boston Scientific, has been on the advisory boards of Medtronic, Inc. and St. Jude, has received honoraria from Medtronic and Boehringer Ingelheim, and has received grants from the National Parkinson Foundation, GlaxoSmithKline, and Medtronic, Inc.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>mild cognitive impairment</topic><topic>Parkinson's disease</topic><topic>systematic review</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Reviews</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1814</start><end>1824</end><total>11</total></extent></part></relatedItem><identifier type="istex">D54A384E259CBCEAF0CE4887C68236F008032EDA</identifier><identifier type="DOI">10.1002/mds.23823</identifier><identifier type="ArticleID">MDS23823</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000112 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000112 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:D54A384E259CBCEAF0CE4887C68236F008032EDA
|texte= MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
}}
| This area was generated with Dilib version V0.6.23. |  |